HC Wainwright Has Positive Estimate for VERA Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Vera Therapeutics to a loss of $1.64 from a projected loss of $1.71, while maintaining a Buy rating and $90 price target.
• Vera reported a Q2 loss of $1.52 per share, beating analysts’ $1.58 loss estimate. However, shares opened at $28.89, down 3.7%, well below their 50-day and 200-day moving averages.
• HC Wainwright expects losses through 2027 before profitability in 2028, projecting EPS of $0.49 in 2028 and stronger earnings thereafter; institutional investors own 99.21% of the stock.

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Stock analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst A. He now expects that the company will post earnings of ($1.64) per share for the quarter, up from their previous estimate of ($1.71). HC Wainwright has a "Buy" rating and a $90.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($6.45) per share. HC Wainwright also issued estimates for Vera Therapeutics' Q4 2026 earnings at ($1.66) EPS, FY2026 earnings at ($6.52) EPS, Q1 2027 earnings at ($1.51) EPS, Q2 2027 earnings at ($1.35) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($0.54) EPS, FY2027 earnings at ($4.38) EPS, FY2028 earnings at $0.49 EPS, FY2029 earnings at $5.21 EPS and FY2030 earnings at $8.79 EPS.

VERA has been the topic of several other research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vera Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group reissued a "buy" rating and set a $90.00 price objective on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Bank of America raised their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a "buy" rating in a research note on Tuesday, July 7th. Jefferies Financial Group reissued a "buy" rating and set a $60.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and issued a $84.00 price objective on shares of Vera Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vera Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $81.15.

Vera Therapeutics Stock Down 3.7%

Shares of VERA opened at $28.89 on Friday. The business's fifty day moving average price is $36.40 and its two-hundred day moving average price is $38.56. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -4.93 and a beta of 0.92. Vera Therapeutics has a 52 week low of $21.04 and a 52 week high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same quarter last year, the firm posted ($1.20) earnings per share.

Hedge Funds Weigh In On Vera Therapeutics

A number of large investors have recently modified their holdings of the business. UBS Group AG boosted its holdings in shares of Vera Therapeutics by 27.9% in the 4th quarter. UBS Group AG now owns 207,289 shares of the company's stock valued at $10,497,000 after buying an additional 45,214 shares during the last quarter. Vanguard Group Inc. raised its position in Vera Therapeutics by 11.9% during the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company's stock worth $180,805,000 after acquiring an additional 379,748 shares in the last quarter. E. Ohman J or Asset Management AB lifted its stake in Vera Therapeutics by 99.5% in the second quarter. E. Ohman J or Asset Management AB now owns 85,777 shares of the company's stock valued at $3,681,000 after acquiring an additional 42,787 shares during the last quarter. Swedbank AB lifted its stake in Vera Therapeutics by 142.4% in the fourth quarter. Swedbank AB now owns 121,200 shares of the company's stock valued at $6,138,000 after acquiring an additional 71,200 shares during the last quarter. Finally, TimesSquare Capital Management LLC acquired a new position in shares of Vera Therapeutics during the 4th quarter worth about $12,785,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the company's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer owned 151,994 shares of the company's stock, valued at $6,429,346.20. This represents a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by company insiders.

Key Headlines Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and projects substantial long-term earnings growth, forecasting EPS of $0.49 in 2028, $5.21 in 2029 and $8.79 in 2030. The firm also modestly improved its 2026 EPS forecast to a loss of $6.52 from $6.79 and narrowed its projected 2026 quarterly losses. HC Wainwright Lowers Vera Therapeutics Price Target
• Neutral Sentiment: HC Wainwright expects Vera Therapeutics to remain unprofitable through 2027, with projected losses narrowing from $6.52 per share in 2026 to $4.38 in 2027. The firm’s forecasts imply a potential transition to profitability in 2028, but that outlook depends on successful clinical and commercial execution. Analysts Offer Insights on Vera Therapeutics
• Negative Sentiment: HC Wainwright cut its price target to $90 from $125, although it retained its Buy rating. The reduction signals lower valuation expectations even though the revised target remains materially above the stock’s recent trading level. Benzinga Analyst Coverage
• Negative Sentiment: The firm reduced its longer-term EPS forecasts, cutting 2027 estimates to a loss of $4.38 from $3.84, 2028 EPS to $0.49 from $2.20, 2029 EPS to $5.21 from $9.11 and 2030 EPS to $8.79 from $10.83. These reductions weaken the anticipated pace of profitability and likely contribute to selling pressure. Wedbush Issues Forecast for Vera Therapeutics

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source